Clinical Trial Update: A Trial of Intratumoral Injections of SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma or Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial investigating intratumoral SD-101 with pembrolizumab in metastatic melanoma or recurrent/metastatic head and neck squamous cell carcinoma; study…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma
• Melanoma

Drugs mentioned

• Pembrolizumab (pembrolizumab)
• SD-101

Snippet

Sponsor: Dynavax Technologies Corporation | Conditions: Metastatic Melanoma, Head Neck Cancer | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2021-08-03